01—Abstract
Summary
Summary of the 8-K filed April 3, 2026. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc. (ABBV) has filed a Form 8-K to provide preliminary information regarding its first quarter 2026 financial results, specifically detailing the impact of acquired In-Process Research & Development (IPR&D) and milestones expenses.
The company anticipates these expenses will negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by approximately $0.41a. This expense, totaling $744 million pre-tax, was not previously included in the company's initial 2026 adjusted diluted EPS guidance, which was based on February 4, 2026, expectations. Despite this one-time charge, AbbVie has updated its full-year 2026 adjusted diluted EPS guidance to a range of $13.96 to $14.16, incorporating the first quarter's impact.
The updated first quarter 2026 adjusted diluted EPS guidance range is now projected at $2.56 to $2.60b. Investors should note that these are preliminary estimates and the final results are subject to financial statement closing procedures. The filing also includes standard forward-looking statement disclaimers highlighting potential risks and uncertainties.
02—Key points
Key Highlights
- AbbVie anticipates a $0.41 negative impact on both GAAP and adjusted non-GAAP diluted EPS for Q1 2026 due to acquired IPR&D and milestones expenses.
- The pre-tax impact of acquired IPR&D and milestones expenses for Q1 2026 is estimated at $744 million.
- The previously issued 2026 adjusted diluted EPS guidance did not account for potential acquired IPR&D and milestones expenses.
- AbbVie has updated its full-year 2026 adjusted diluted EPS guidance to a range of $13.96 - $14.16, now including the Q1 expense impact.
- The updated Q1 2026 adjusted diluted EPS guidance range, including the expense impact, is set at $2.56 - $2.60.
- The reported results are preliminary and subject to finalization and financial statement closing procedures.
- Exhibit 99.1 contains updated guidance, including the estimated acquired IPR&D and milestones expense for Q1 2026.
03—Questions
Frequently Asked Questions
What is the primary reason for the negative EPS impact in Q1 2026?
The negative impact on earnings per share in the first quarter of 2026 is due to acquired In-Process Research & Development (IPR&D) and milestones expenses totaling $744 million on a pre-tax basis.
How does this acquired IPR&D and milestones expense affect AbbVie's full-year 2026 guidance?
AbbVie has updated its full-year 2026 adjusted diluted earnings per share guidance to a range of $13.96 to $14.16, which now incorporates the estimated impact of the first quarter's acquired IPR&D and milestones expense.
Are the reported Q1 2026 results final?
No, the results for the quarter ended March 31, 2026, have not been finalized and are subject to the company's financial statement closing procedures. There is a possibility that final results may differ from these preliminary estimates.
Does this expense affect AbbVie's non-GAAP earnings?
Yes, the acquired IPR&D and milestones expense impacts both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share by an estimated $0.41 on a pre-tax basis for the first quarter of 2026.
04—Continue